The European Commission approves Regeneron’s extended Libtayo dosing, allowing 700 mg every six weeks across six cancer indications, with shorter infusion options.
Written By: Creola Gonsalves, MS Biotech
Reviewed By: Pharmacally Editorial Team
The European Commission (EC) has approved an alternative dosing regimen for Libtayo (cemiplimab), allowing eligible adults treated across all approved skin, lung, and cervical cancer indications in the European Union to transition to a 700 mg intravenous dose every six weeks after an initial 12-week treatment period. The approval also permits shorter infusion times for the 350 mg dose, potentially reducing administration time by up to half, from 30 minutes to 15 minutes.
EC Approval Introduces Flexible Dosing Options
Libtayo is a fully human monoclonal antibody that blocks programmed cell death protein 1 (PD-1), an immune checkpoint receptor on T cells. By inhibiting PD-1 signalling, cemiplimab helps restore T-cell activity against cancer cells.
Under the newly approved regimen, patients initially receive Libtayo 350 mg intravenously every three weeks, with each infusion administered over 30 minutes. After completing the first 12 weeks of treatment, patients can transition to a 700 mg dose every six weeks, also administered over 30 minutes. While the six-week maintenance schedule was previously approved in the EU and US specifically for adjuvant high-risk cutaneous squamous cell carcinoma (CSCC), this latest decision extends that dosing flexibility across all of Libtayo’s remaining EU-approved indications.
The EC has additionally approved an option to shorten subsequent infusions of Libtayo 350 mg by up to half—from 30 minutes to 15 minutes—for patients who tolerate their first 30-minute infusion. This flexibility applies to patients continuing the three-week dosing schedule.
The revised regimen provides an alternative to the existing administration schedule rather than changing the approved cancer indications or establishing a new treatment approach. Its practical significance lies in reducing the frequency of hospital visits and potentially shortening infusion appointments.
Approval Supported by Clinical Data and PK/PD Modelling
The regulatory decision draws on safety and efficacy evidence from Libtayo’s clinical development programme, integrated with pharmacokinetic (PK) and pharmacodynamic (PD) modelling and simulation.
The modelling and simulation data support the alternative dosing schedule by evaluating drug exposure and the relationship between dosing intervals and pharmacological activity. This approach provides regulatory support for extending the interval between maintenance doses without requiring a new efficacy trial to establish a separate clinical benefit.
Regeneron did not report new clinical efficacy outcomes, comparative response rates, or additional safety findings alongside this approval. The announcement also did not identify a dedicated trial phase or a specific study population for the alternative dosing regimen. Therefore, the decision should be interpreted as a dosing and administration update supported by existing clinical evidence and pharmacological modelling, rather than a new demonstration of improved anticancer efficacy.
Approval Covers Six EU Cancer Indications
The alternative dosing and infusion options apply across all six approved Libtayo indications in the European Union:
- Advanced cutaneous squamous cell carcinoma (CSCC): Monotherapy for adults with metastatic or locally advanced disease who are not candidates for curative surgery or radiation.
- Adjuvant CSCC: Monotherapy (for up to 48 weeks) following surgery and radiation in adults at high risk of recurrence, subject to approved selection criteria.
- Advanced basal cell carcinoma (BCC): Monotherapy for adults with locally advanced or metastatic disease following progression on, or intolerance to, a hedgehog pathway inhibitor.
- First-line NSCLC monotherapy: Monotherapy for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC), PD-L1 expression of at least 50%, and no EGFR, ALK, or ROS1 aberrations.
- First-line NSCLC combination therapy: In combination with platinum-based chemotherapy for adults with locally advanced or metastatic NSCLC, PD-L1 expression of at least 1%, and no EGFR, ALK, or ROS1 aberrations.
- Recurrent or metastatic cervical cancer: Monotherapy for adults whose disease has progressed during or after platinum-based chemotherapy.
Clinical Impact and US Regulatory Outlook
The European approval expands administration flexibility across the drug’s established oncology indications. For patients receiving long-term immunotherapy, fewer infusion appointments could reduce treatment-related logistical demands, while shorter infusions may improve clinic scheduling and patient convenience.
In the United States, where the six-week dosing option is already available for adjuvant high-risk CSCC, Regeneron has submitted a supplemental Biologics License Application (sBLA) to expand the alternative dosing regimen and shorter infusion option across its other approved indications. The US Food and Drug Administration (FDA) is expected to make a decision in March 2027, which will determine whether this broader administration flexibility becomes available to eligible US patients.
Reference
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications, Regeneron, 17 November 2026
About the Writer
Creola Gonsalves (Linkedin) is an M.S. Biotechnology postgraduate with a strong interest in clinical research, evidence interpretation, and healthcare writing, with a focus on translating life-science knowledge into meaningful real-world insights.
She is trained in Good Clinical Practice (GCP), clinical research principles, and critical interpretation of randomized clinical trials, with certifications from NIH and Stanford University.
Her research background in biotechnological applications and microbial research strengthens her ability to understand scientific evidence and develop clear, accurate, and research-driven healthcare content.
